{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:06:38Z","timestamp":1791342398352,"version":"4.3.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95159"],"award-info":[{"award-number":["N01-HC-95159"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC- 95160"],"award-info":[{"award-number":["N01-HC- 95160"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95161"],"award-info":[{"award-number":["N01-HC-95161"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95162"],"award-info":[{"award-number":["N01-HC-95162"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95163"],"award-info":[{"award-number":["N01-HC-95163"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95164"],"award-info":[{"award-number":["N01-HC-95164"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95165"],"award-info":[{"award-number":["N01-HC-95165"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95166"],"award-info":[{"award-number":["N01-HC-95166"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95167"],"award-info":[{"award-number":["N01-HC-95167"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95168"],"award-info":[{"award-number":["N01-HC-95168"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["N01-HC-95169"],"award-info":[{"award-number":["N01-HC-95169"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Center for Research Resources National Institutes of Health Intramural Research Program","award":["UL1-TR-000040"],"award-info":[{"award-number":["UL1-TR-000040"]}]},{"name":"National Center for Research Resources National Institutes of Health Intramural Research Program","award":["UL1-TR-001079"],"award-info":[{"award-number":["UL1-TR-001079"]}]},{"name":"Bayer Healthcare for the use of gadolinium contrast agent"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Emerging research indicates that high HDL-C levels might not be cardioprotective, potentially worsening cardiovascular disease (CVD)\u00a0outcomes. Yet, there\u00a0is no data on HDL-C's association with other CVD risk factors like myocardial fibrosis, a key aspect of cardiac remodeling predicting negative outcomes. We therefore aimed to study the association between HDL-C levels with interstitial myocardial fibrosis (IMF) and myocardial scar measured by CMR T1-mapping and late-gadolinium enhancement (LGE), respectively. There were 1863 participants (mean age of 69\u00a0years) who had both serum HDL-C measurements and underwent CMR. Analysis was done among those with available indices of interstitial fibrosis (extracellular volume fraction [ECV]; N\u2009=\u20091172 and native-T1; N\u2009=\u20091863) and replacement fibrosis by LGE (N\u2009=\u20091172). HDL-C was analyzed as both logarithmically-transformed and categorized into\u2009&lt;\u200940 (low),40\u201359 (normal), and \u2265\u200960mg\/dL (high). Multivariable linear and logistic regression models were constructed to assess the associations of HDL-C with CMR-obtained measures of IMF, ECV% and native-T1 time, and myocardial scar, respectively. In the fully adjusted model, each 1-SD increment of log HDL-C was associated with a 1% increment in ECV% (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01) and an 18-ms increment in native-T1 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). When stratified by HDL-C categories, those with high HDL-C (\u2265\u200960mg\/dL) had significantly higher ECV (\u03b2\u2009=\u20090.5%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01) and native-T1 (\u03b2\u2009=\u20097\u00a0ms,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01) compared with those with normal HDL-C levels. Those with low HDL-C were not associated with IMF. Results remained unchanged after excluding individuals with a history of myocardial infarction. Neither increasing levels of HDL-C nor any HDL-C category was associated with the prevalence of myocardial scar. Increasing levels of HDL-C were associated with increased markers of IMF, with those with high levels of HDL-C being linked to subclinical fibrosis in a community-based setting.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-46811-8","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:04:07Z","timestamp":1700201047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Higher HDL cholesterol levels are associated with increased markers of interstitial myocardial fibrosis in the MultiEthnic Study of Atherosclerosis\u00a0(MESA)"],"prefix":"10.1038","volume":"13","author":[{"given":"Omar","family":"Chehab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Akl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Zeitoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath","family":"Ambale-Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Tracy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger S.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy S.","family":"Post","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao A. C.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"issue":"7","key":"46811_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamacardio.2022.0924","volume":"7","author":"SS Khan","year":"2022","unstructured":"Khan, S. S. & Fonarow, G. C. Very elevated high-density lipoprotein cholesterol and mortality-the good gone bad?. JAMA Cardiol. 7(7), 681 (2022).","journal-title":"JAMA Cardiol."},{"issue":"8","key":"46811_CR2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41569-022-00743-4","volume":"19","author":"I Fern\u00e1ndez-Ruiz","year":"2022","unstructured":"Fern\u00e1ndez-Ruiz, I. Very high HDL-C levels are associated with higher mortality in patients with CAD. Nat. Rev. Cardiol. 19(8), 504 (2022).","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"46811_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11883-020-00902-3","volume":"23","author":"A Rodriguez","year":"2021","unstructured":"Rodriguez, A. High HDL-cholesterol paradox: SCARB1-LAG3-HDL axis. Curr. Atheroscler. Rep. 23(1), 5 (2021).","journal-title":"Curr. Atheroscler. Rep."},{"issue":"7","key":"46811_CR4","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamacardio.2022.0912","volume":"7","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk populations. JAMA Cardiol. 7(7), 672\u2013680 (2022).","journal-title":"JAMA Cardiol."},{"issue":"32","key":"46811_CR5","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","volume":"38","author":"CM Madsen","year":"2017","unstructured":"Madsen, C. M., Varbo, A. & Nordestgaard, B. G. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur. Heart J. 38(32), 2478\u20132486 (2017).","journal-title":"Eur. Heart J."},{"issue":"12","key":"46811_CR6","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1161\/CIRCULATIONAHA.122.059325","volume":"146","author":"MP Bonaca","year":"2022","unstructured":"Bonaca, M. P. et al. Randomized, placebo-controlled phase 2b study to evaluate the safety and efficacy of recombinant human lecithin cholesterol acyltransferase in acute ST-segment-elevation myocardial infarction: Results of REAL-TIMI 63B. Circulation 146(12), 907\u2013916 (2022).","journal-title":"Circulation"},{"issue":"9","key":"46811_CR7","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.jcmg.2019.03.018","volume":"12","author":"S Rosmini","year":"2019","unstructured":"Rosmini, S. et al. The effect of blood composition on T1 mapping. JACC Cardiovasc. Imaging 12(9), 1888\u20131890 (2019).","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"9","key":"46811_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/aje\/kwf113","volume":"156","author":"DE Bild","year":"2002","unstructured":"Bild, D. E. et al. Multi-ethnic study of atherosclerosis: Objectives and design. Am. J. Epidemiol. 156(9), 871\u2013881 (2002).","journal-title":"Am. J. Epidemiol."},{"issue":"10","key":"46811_CR9","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/ehjci\/jeac010","volume":"23","author":"MD Marques","year":"2022","unstructured":"Marques, M. D. et al. Myocardial fibrosis by T1 mapping magnetic resonance imaging predicts incident cardiovascular events and all-cause mortality: The Multi-Ethnic Study of Atherosclerosis. Eur. Heart J. Cardiovasc. Imaging 23(10), 1407\u20131416 (2022).","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"issue":"14","key":"46811_CR10","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.jacc.2013.05.078","volume":"62","author":"CY Liu","year":"2013","unstructured":"Liu, C. Y. et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 62(14), 1280\u20131287 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"18","key":"46811_CR11","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2015.14849","volume":"314","author":"EB Turkbey","year":"2015","unstructured":"Turkbey, E. B. et al. Prevalence and correlates of myocardial scar in a US cohort. JAMA 314(18), 1945\u20131954 (2015).","journal-title":"JAMA"},{"key":"46811_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jcmg.2022.06.011","volume":"16","author":"Z Raisi-Estabragh","year":"2022","unstructured":"Raisi-Estabragh, Z. et al. Incident clinical and mortality associations of myocardial native T1 in the UK biobank. JACC Cardiovasc. Imaging 16, 450\u2013460 (2022).","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"11 Pt 2","key":"46811_CR13","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.jcmg.2019.06.031","volume":"12","author":"AA Robinson","year":"2019","unstructured":"Robinson, A. A., Chow, K. & Salerno, M. Myocardial T1 and ECV measurement: Underlying concepts and technical considerations. JACC Cardiovasc. Imaging 12(11 Pt 2), 2332\u20132344 (2019).","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"2","key":"46811_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/mrm.1910220230","volume":"22","author":"DL White","year":"1991","unstructured":"White, D. L. Paramagnetic iron (III) MRI contrast agents. Magn. Reason. Med. 22(2), 309\u2013312 (1991).","journal-title":"Magn. Reason. Med."},{"issue":"1","key":"46811_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jcmg.2015.12.001","volume":"9","author":"VO Puntmann","year":"2016","unstructured":"Puntmann, V. O. et al. T1-mapping and outcome in nonischemic cardiomyopathy: All-cause mortality and heart failure. JACC Cardiovasc. Imaging 9(1), 40\u201350 (2016).","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"10","key":"46811_CR16","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/CIRCULATIONAHA.111.089409","volume":"126","author":"TC Wong","year":"2012","unstructured":"Wong, T. C. et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 126(10), 1206\u20131216 (2012).","journal-title":"Circulation"},{"issue":"4","key":"46811_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094585","volume":"9","author":"N Kaur","year":"2014","unstructured":"Kaur, N. et al. Effect of HDL-raising drugs on cardiovascular outcomes: A systematic review and meta-regression. PLoS ONE 9(4), e94585 (2014).","journal-title":"PLoS ONE"},{"issue":"24","key":"46811_CR18","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden, W. E. et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365(24), 2255\u20132267 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"46811_CR19","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357(21), 2109\u20132122 (2007).","journal-title":"N. Engl. J. Med."},{"key":"46811_CR20","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2022","unstructured":"von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T. & Catapano, A. L. High-density lipoprotein revisited: biological functions and clinical relevance. Eur. Heart J. 44, 1394\u20131407 (2022).","journal-title":"Eur. Heart J."},{"issue":"4","key":"46811_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","volume":"38","author":"T Speer","year":"2013","unstructured":"Speer, T. et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 38(4), 754\u2013768 (2013).","journal-title":"Immunity"},{"issue":"17","key":"46811_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.88628","volume":"1","author":"D Golden","year":"2016","unstructured":"Golden, D. et al. Lymphocyte activation gene 3 and coronary artery disease. JCI Insight 1(17), e88628 (2016).","journal-title":"JCI Insight"},{"issue":"1","key":"46811_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s42003-022-03304-0","volume":"5","author":"A Manichaikul","year":"2022","unstructured":"Manichaikul, A. et al. Lymphocyte activation gene-3-associated protein networks are associated with HDL-cholesterol and mortality in the Trans-omics for Precision Medicine program. Commun. Biol. 5(1), 362 (2022).","journal-title":"Commun. Biol."},{"issue":"25","key":"46811_CR24","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1161\/CIRCULATIONAHA.122.059863","volume":"145","author":"M Abdellatif","year":"2022","unstructured":"Abdellatif, M. et al. Fine-tuning cardiac insulin-like growth factor 1 receptor signaling to promote health and longevity. Circulation 145(25), 1853\u20131866 (2022).","journal-title":"Circulation"},{"issue":"11","key":"46811_CR25","doi-asserted-by":"publisher","first-page":"R1045","DOI":"10.1152\/ajpregu.00309.2015","volume":"310","author":"M Hellstr\u00f6m","year":"2016","unstructured":"Hellstr\u00f6m, M. et al. Cardiac hypertrophy and decreased high-density lipoprotein cholesterol in Lrig3-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310(11), R1045\u2013R1052 (2016).","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"9","key":"46811_CR26","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1161\/ATVBAHA.118.310946","volume":"38","author":"I Muthuramu","year":"2018","unstructured":"Muthuramu, I. et al. Hepatocyte-specific SR-BI gene transfer corrects cardiac dysfunction in scarb1-deficient mice and improves pressure overload-induced cardiomyopathy. Arterioscler. Thromb. Vasc. Biol. 38(9), 2028\u20132040 (2018).","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46811-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T06:23:32Z","timestamp":1700202212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-46811-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["46811"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-46811-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3299344\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"assertion":[{"value":"26 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R. reports inventorship rights to patents held by the University of Connecticut Health and Lipid Genomics. A.R. is the founder of Lipid Genomics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20115"}}